The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in Pharmaceuticals: Neuro-degenerative receptor binding drug compositions.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Neuro-degenerative receptor binding drug compositions is a key innovation area in biosimilars
The neuro-degenerative receptor binding drugs bind to and modulate the action of various receptors that are associated with neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Glucagon-like peptide 1 (GLP-1) receptor agonists, brain derived neurotrophic factor (BDNF) receptor agonists, and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists are the novel neuro-degenerative receptor binding drugs under development.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 150+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of neuro-degenerative receptor binding drug compositions.
Key players in neuro-degenerative receptor binding drug compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to neuro-degenerative receptor binding drug compositions
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Biogen||340||Unlock company profile|
|AC Immune||309||Unlock company profile|
|F. Hoffmann-La Roche||293||Unlock company profile|
|AbbVie||279||Unlock company profile|
|Prothena||180||Unlock company profile|
|Lundbeck Foundation||168||Unlock company profile|
|BioArctic||146||Unlock company profile|
|Axon Neuroscience||124||Unlock company profile|
|TauRx Pharmaceuticals||99||Unlock company profile|
|Johnson & Johnson||87||Unlock company profile|
|Neurimmune Holding||81||Unlock company profile|
|Abbott Laboratories||80||Unlock company profile|
|Bristol-Myers Squibb||77||Unlock company profile|
|Eli Lilly and||72||Unlock company profile|
|UCB||67||Unlock company profile|
|Forschungszentrum Julich||67||Unlock company profile|
|Vivoryon Therapeutics||67||Unlock company profile|
|Proteome Sciences||64||Unlock company profile|
|Eisai||54||Unlock company profile|
|OncoTherapy Science||54||Unlock company profile|
|C2N Diagnostics||51||Unlock company profile|
|Takeda Pharmaceutical||47||Unlock company profile|
|AFFiRiS||45||Unlock company profile|
|PTC Therapeutics||43||Unlock company profile|
|Pfizer||40||Unlock company profile|
|Centre National de la Recherche Scientifique||37||Unlock company profile|
|AstraZeneca||36||Unlock company profile|
|Max-Planck-Gesellschaft||36||Unlock company profile|
|Cedars-Sinai Health System||36||Unlock company profile|
|Acorda Therapeutics||34||Unlock company profile|
|ProMIS Neurosciences||33||Unlock company profile|
|Sage Therapeutics||32||Unlock company profile|
|Tao Health Life Pharma||32||Unlock company profile|
|Perrigo||30||Unlock company profile|
|Ionis Pharmaceuticals||28||Unlock company profile|
|Nestle||28||Unlock company profile|
|Merck & Co||28||Unlock company profile|
|CommonSpirit Health||25||Unlock company profile|
|Grifols||24||Unlock company profile|
|Banyan Biomarkers||22||Unlock company profile|
|Massachusetts General Hospital||21||Unlock company profile|
|Immungenetics||21||Unlock company profile|
|GeNeuro||20||Unlock company profile|
|German Cancer Research Center||20||Unlock company profile|
|MorphoSys||20||Unlock company profile|
|National Research Council of Canada||20||Unlock company profile|
|Meiji Holdings||19||Unlock company profile|
|Annexon||19||Unlock company profile|
|General Hospital||19||Unlock company profile|
|OPKO Health||19||Unlock company profile|
Source: GlobalData Patent Analytics
Biogen is the leading patent filer in neuro-degenerative receptor binding drug compositions and has more than 15 neurodegenerative drugs in development. It has recently received new drug approval from the US FDA for an anti-beta-amyloid monoclonal antibody (Aduhelm) for the treatment of AD. AC Immune and F. Hoffmann-La Roche are the other key patent filers in neuro-degenerative receptor binding drug compositions.
In terms of application diversity, PTC Therapeutics is the top company, followed by AFFiRiS and TauRx Pharmaceuticals. By means of geographic reach, Max-Planck-Gesellschaft holds the top position. MorphoSys and National Research Council of Canada stand in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.